| Literature DB >> 32387288 |
Brendan Miller1, Su-Jeong Kim1, Hiroshi Kumagai2, Hemal H Mehta1, Wang Xiang1, Jiali Liu1, Kelvin Yen1, Pinchas Cohen3.
Abstract
Mitochondrial-derived peptides (MDPs) are a novel class of bioactive microproteins that modify cell metabolism. The the eight MDPs that been characterized (e.g., humanin, MOTS-c, SHLPs1-6) attenuate disease pathology including Alzheimer's disease, prostate cancer, macular degeneration, cardiovascular disease, and diabetes. The association between disease and human genetic variation in MDPs is underexplored, although two polymorphisms in humanin and MOTS-c associate with cognitive decline and diabetes, respectively, suggesting a precise role for MDPs in disease-modification. There could be hundreds of additional MDPs that have yet to be discovered. Altogether, MDPs could explain unanswered biological and metabolic questions and are part of a growing field of novel microproteins encoded by small open reading frames. In this review, the current state of MDPs are summarized with an emphasis on biological and therapeutic implications.Entities:
Keywords: Microproteins; Mitochondrial-derived peptides; Small open reading frames
Mesh:
Substances:
Year: 2020 PMID: 32387288 PMCID: PMC7778388 DOI: 10.1016/j.yexcr.2020.112056
Source DB: PubMed Journal: Exp Cell Res ISSN: 0014-4827 Impact factor: 3.905